Effects of Marine Phospholipids Extract on the Lipid Levels of Metastatic and Nonmetastatic Prostate Cancer Patients
Table 4
Results of fatty acid analysis with GC.
Fatty acid
Before MPL (%)
After MPL (%)
Relative change of respective FA†
TG-fraction
Myristic acid-C14:0
1.9 (0.5–5.6)
2.2 (0.7–23.5)
+16%
<0.01
Palmitic acid-C16:0
23.9 (14.7–35.7)
23.2 (14.7–36.9)
−3%
<0.05
Stearic acid-C18:0
3.7 (1.5–8)
3.7 (1.9–7.2)
0%
n.s.
Oleic acid-C18:1
34.1 (25.4–43.2)
32 (23.1–45.3)
−6%
<0.01
Linoleic acid (LA)-C18:2
27.6 (12.9–46.1)
29.6 (15.8–47.9)
+7%
<0.01
α-Linolenic acid (ALA)-C18:3
0.8 (0.1–9.6)
1 (0–5)
+25%
<0.001
Arachidonic acid (AA)*-C20:4
4.1 (1.4–7.8)
3.6 (0.5–8.4)
−12%
<0.01
Eicosapentaenoic acid (EPA)-C20:5
0.6 (0.1–2.1)
1 (0.2–3.4)
+67%
<0.001
Docosahexaenoic acid (DHA)-C22:6
0.7 (0.2–2.1)
1 (0.1–2.1)
+43%
<0.001
of median values
97.4
97.3
PL-fraction
Myristic acid-C14:0
0.3 (0.1–0.7)
0.4 (0.2–0.7)
+33%
<0.001
Palmitic acid-C16:0
25.4 (15.9–30)
24.9 (20.5–28.6)
−2%
<0.01
Stearic acid-C18:0
11.7 (8.4–16.3)
12.1 (8.4–15.8)
+3%
<0.001
Oleic acid-C18:1
10.6 (5.6–14.2)
10.7 (7.4–15.6)
0%
n.s.
Linoleic acid (LA)-C18:2
17.4 (11.2–24.3)
18.5 (8.3–23.9)
+6%
<0.01
-linolenic acid (ALA)-C18:3
0.2 (0–3.4)
0.3 (0–0.9)
+50%
<0.001
Arachidonic acid (AA)*-C20:4
9.3 (3.2–14.8)
8.5 (4.3–14.4)
−9%
<0.001
Eicosapentaenoic acid (EPA)-C20:5
0.8 (0.2–3.4)
1.4 (0.5–4.1)
+75%
<0.001
Docosahexaenoic acid (DHA)-C22:6
3 (0.9–6.1)
3.6 (1.5–5.9)
+20%
<0.001
sum of median values
78.7
75.4
*Normal distribution. †Change of FAs after MPL supplementation based on the median initial values. Median relative values of each FA before and after MPL supplementation in the study population (). Since most of the data is not normally distributed, all values are given in median (min–max). Since C:17 lysophosphatidylcholine was used as internal standard, the results of C:17 are not shown in the table. C17 stays mostly in the PL fraction; therefore the values of the shown FAs (% of each FA) are not based on a 100%.
